Short abstract
LINKED CONTENT
This article is linked to King et al and Benson‐Pope and Greary papers. To view these articles, visit https://doi.org/10.1111/apt.15701 and https://doi.org/10.1111/apt.15759.
Benson‐Pope et al have highlighted the concerns that many patients with IBD, along with their medical teams, face during the coronavirus pandemic. 1 Immunosuppression has been the mainstay of moderate to severe IBD management for decades. With large IBD populations around the world, the need to protect such potentially vulnerable patients from coronavirus disease 2019 (COVID‐19) is vital.
The novelty of COVID‐19 has thrown up many challenges for the clinician, including how best to manage medications and what new onset symptoms may mean, given that COVID‐19 can cause diarrhoea and abdominal pain, and that viral illnesses can lead to IBD flares. 2 , 3 Although no evidence currently suggests that COVID‐19 can induce flares in IBD, avoidance of COVID‐19 in IBD, especially in those who are immunosuppressed or have active disease, is crucial. Benson‐Pope et al, have highlighted the consensus statements from the International Organisation for the study of Inflammatory Bowel Disease (IOIBD) concerning IBD medication and COVID‐19; however, a degree of disagreement exemplifies the lack of knowledge and a degree of uncertainty concerning how best to manage patients. 4 Several national and international societies and charities have given advice on IBD and COVID‐19 and many governments have been clear on the need for social distancing. 5 , 6 , 7 , 8
Given the increasing prevalence of IBD, not only patients but also many healthcare professionals will be living with IBD. 9 With health systems around the world coming under strain, adequate personal protective equipment may not always be readily available to healthcare professionals with IBD. With out‐patient appointments and monitoring being postponed, IBD medical teams and patients must be alert to the evolving guidance and take all necessary precautions in the very different healthcare environment we now all work in.
ACKNOWLEDGEMENTS
The authors' declarations of personal and financial interests are unchanged from those in the original article9.
REFERENCES
- 1. Benson‐Pope SJ, Gearry RB. Editorial: increasing IBD prevalence and its complications in the context of the COVID‐19 pandemic. Aliment Pharmacol Ther. 2020;51:1441‐1442. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Song Y, Liu P, Shi XL, et al. SARS‐CoV‐2 induced diarrhoea as onset symptom in patient with COVID‐19. Gut. 2020:gutjnl‐2020‐320891 10.1136/gutjnl-2020-320891 [DOI] [PubMed] [Google Scholar]
- 3. Rahier J‐F, Papay P, Salleron J, et al. Influenza A (H1N1)v infection in patients with inflammatory bowel disease: a case series. Aliment Pharmacol Ther. 2011;33:499‐500. [DOI] [PubMed] [Google Scholar]
- 4. IOIBD update on COVID19 for patients with Crohn's disease and ulcerative colitis. 2020. https://www.ioibd.org/ioibd-update-on-covid19-for-patients-with-crohns-disease-and-ulcerative-colitis/. Accessed April 8, 2020.
- 5. Guidance on social distancing for everyone in the UK. https://www.gov.uk/government/publications/covid-19-guidance-on-social-distancing-and-for-vulnerable-people/guidance-on-social-distancing-for-everyone-in-the-uk-and-protecting-older-people-and-vulnerable-adults. Accessed April 8, 2020.
- 6. Unite against COVID‐19; vulnerable people. https://covid19.govt.nz/individuals-and-households/health-and-wellbeing/vulnerable-people/. Accessed April 8, 2020.
- 7. BSG expanded consensus advice for the management of IBD during the COVID‐19 pandemic. 2020. https://www.bsg.org.uk/covid-19-advice/bsg-advice-for-management-of-inflammatory-bowel-diseases-during-the-covid-19-pandemic/. Accessed April 8, 2020.
- 8. New guidance for people with Crohn's and colitis on level of risk of complications from COVID‐19, and what you should do as a result. 2020. https://www.crohnsandcolitis.org.uk/news/advice-for-people-with-crohns-and-colitis-self-isolation-social-distancing. Accessed April 8, 2020.
- 9. King D, Reulen RC, Thomas T, et al. Changing patterns in the epidemiology and outcomes of inflammatory bowel disease in the United Kingdom: 2000–2018. Aliment Pharmacol Ther. 2020;51:922‐934. [DOI] [PubMed] [Google Scholar]